ALL >> Health >> View Article
Forecast Insight: Multiple Sclerosis - Tysabri To Prevail Despite Safety Setbacks
Spurred by uptake of Biogen Idec and Elan's Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva's Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increased 15.1% from 2006 to $5.3 billion in 2007.
Scope of this report
This report gives a strategic analysis of the likely impact that recent events will have on the future multiple sclerosis market
Includes multiple sclerosis-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
Provides a global market snapshot by including multiple sclerosis-specific sales analysis for leading brands outside the seven major markets
Key conclusions are supported by key opinion leader comment
Research and analysis highlights
Despite the recent confirmation of two new cases of progressive multifocal leukoencephalopathy (PML), with a much stronger 200708 enrollment rate than previously anticipated and a greater level of confidence among opinion leaders, It has upgraded its Tysabri's forecast.
It remains highly positive ...
... on Novartis's FTY720 (fingolimod). FTY720 is expected to achieve the greatest sales of all current late-stage pipeline products. However, sales growth will be restricted from 2012 by the later launch of additional oral pipeline disease-modifiers, which will represent tough direct competition.
Genzyme and Bayer Schering's alemtuzumab (Campath) has been added to this latest multiple sclerosis forecast. Potentially positioned in both the earliest stages of the disease and for rapidly progressing patients refractory on other therapies, a poor perceived safety profile and an assumed low price-point, will limit returns from this market.
For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=82018
Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131
Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.
Bharat BooK Bureau is the leading market research information aggregator which provides reports, Company profiles, newletters, country info. and online databases for the past twenty years to corportate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies. It helps global companies to know different market before starting up business / expanding in different countries across the world. www.bharatbook.com is one stop shop for the business intelligence information requirements.
Add Comment
Health Articles
1. The Vital Role Of Hospital Elevators In Modern Healthcare FacilitiesAuthor: Harsh Shahi
2. Unlocking The Benefits Of A 3-day Water Fast: A Journey To Inflammation Reduction, Longevity, And Gut Healing
Author: Dr. Nick Zyrowski
3. Is Credelio Plus Good For Dogs?
Author: VetSupply
4. Best Dental Clinic In Nagpur. Dr. Suryawanshi’s Dental Clinic
Author: Priyanka Suryawanshi
5. What Is The Difference Between Frontline Plus And Frontline Original For Dogs?
Author: VetSupply
6. What Is Icsi Treatment And Its Cost?
Author: SCI IVF Hospital
7. Is Advantage For Dogs Any Good?
Author: VetSupply
8. What Is An Advantage For Cats Medicine?
Author: VetSupply
9. Prioritise Your Health: Get An Essential Health Checkup In Thane
Author: Dr. Vaidya’s Laboratory
10. Why Does My Nose Run When I Eat? Symptoms And Treatment
Author: AllergyX
11. What Is Advantix Used For In Dogs?
Author: VetSupply
12. The Healing Power Of Hot Tubs: 7 Health Benefits You Didn’t Know About
Author: Andrew Strauss
13. Write A 1500 Words Blog On This Topic - Does Frontline Plus Really Work On Cats?
Author: VetSupply
14. Maternity Hospital In Jaipur
Author: YATIKA
15. The Importance Of A First Aid Dressing Kit In Emergencies
Author: medguard